secwatch / observer
8-K filed November 15, 2023, 6:59 PM ET ticker TSHA CIK 0001806310
other material confidence high sentiment neutral materiality 0.50

Taysha Gene Therapies stockholders approve doubling authorized common stock to 400M shares

Taysha Gene Therapies, Inc.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Taysha Gene Therapies, Inc.: Increased authorized shares of common stock from 200,000,000 to 400,000,000 (effective 2023-11-15).

Change
charter amendment
Effective
2023-11-15
Exact text from the filing
On November 15, 2023, Taysha Gene Therapies, Inc. (the “ Company ”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended to date, to increase the authorized number of shares of the Company’s common stock from 200,000,000 shares to 400,000,000 shares.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Taysha Gene Therapies, Inc. shareholders approved Approval of an amendment to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000. at the 2023-11-15 meeting.

Proposal
charter amendment
Outcome
passed
Meeting
2023-11-15
Exact text from the filing
Proposal No. 1: Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended to date, to increase the number of authorized shares of the Company's common stock from 200,000,000 to 400,000,000. The votes were cast as follows: Votes For Votes Against Abstained Amendment to effectuate an authorized shares increase 133,386,292 1,370,285 157,132
View on SEC.gov

Browse all governance changes →

Taysha Gene Therapies, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-23-277914
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.